Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Acelyrin Inc (NQ: SLRN ) 4.240 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Apr 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 657,192 Open 4.250 Bid (Size) 4.300 (70) Ask (Size) 4.600 (15) Prev. Close 4.240 Today's Range 4.180 - 4.340 52wk Range 4.180 - 29.88 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023 March 28, 2024 SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights March 28, 2024 From ACELYRIN, INC. Via GlobeNewswire Performance YTD -46.60% -46.60% 1 Month -37.19% -37.19% 3 Month -40.70% -40.70% 6 Month -55.18% -55.18% 1 Year -81.96% -81.96% More News Read More Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million March 27, 2024 From Avalo Therapeutics Via GlobeNewswire Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients March 20, 2024 Via Benzinga ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease March 20, 2024 From ACELYRIN, INC. Via GlobeNewswire Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study March 11, 2024 Via Benzinga ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis March 11, 2024 From ACELYRIN, INC. Via GlobeNewswire ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients March 11, 2024 From ACELYRIN, INC. Via GlobeNewswire ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications February 15, 2024 From ACELYRIN, INC. Via GlobeNewswire Acelyrin (SLRN) Investor Update: Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline January 16, 2024 Via NewMediaWire Topics Lawsuit Exposures Financial Legal SLRN DEADLINE TOMORROW: ROSEN, A LEADING NATIONAL FIRM, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN January 15, 2024 Via NewMediaWire Topics Lawsuit Exposures Financial Legal SLRN DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN January 14, 2024 Via NewMediaWire Topics Lawsuit Exposures Financial Legal SLRN DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN January 13, 2024 Via NewMediaWire Topics Lawsuit Exposures Financial Legal ACELYRIN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Acelyrin, Inc. and Encourages Investors to Contact the Firm January 12, 2024 From Bragar Eagel & Squire Via GlobeNewswire SLRN IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action SLRN January 12, 2024 Via NewMediaWire Topics Lawsuit Exposures Financial Legal SLRN DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors with Losses in Excess of $100k to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN January 11, 2024 Via NewMediaWire Topics Lawsuit Exposures Financial Legal Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Acelyrin, and Beauty Health and Encourages Investors to Contact the Firm January 10, 2024 From Bragar Eagel & Squire Via GlobeNewswire SLRN IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN January 10, 2024 Via NewMediaWire Topics Lawsuit Exposures Financial Legal Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline January 10, 2024 Via NewMediaWire Topics Lawsuit Exposures Financial Legal ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options January 10, 2024 From Faruqi & Faruqi LLP Via GlobeNewswire Final Deadline Approaching for SLRN Investors: Kessler Topaz Meltzer & Check, LLP Reminds Acelyrin, Inc. (SLRN) Investors of Class Action Lawsuit Deadline on January 16, 2024 January 08, 2024 From Kessler Topaz Meltzer & Check, LLP Via Business Wire ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SLRN January 08, 2024 From The Rosen Law Firm PA Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against James River, Acelyrin, and Beauty Health and Encourages Investors to Contact the Firm January 06, 2024 From Bragar Eagel & Squire Via GlobeNewswire ROSEN, A TOP RANKED LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN January 06, 2024 Via NewMediaWire Topics Lawsuit Exposures Financial Legal ACELYRIN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options January 05, 2024 From Faruqi & Faruqi LLP Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.